Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Policy China Government Payers

China New Government Policies Taking Shape As Two Sessions Underway

New reality, old woos

  • Analysis

Executive Summary

Moderate growth goal and lingering impact from COVID policies dampen prospects of a quick recovery for China.

You may also be interested in...



China Business Pessimism Grows Amid COVID Origin Assessment, Congressional Hearing

Simmering US-China tensions dash hopes that a recent border reopening will put many collaborations back on track, even as more than half foreign businesses now downgrade the importance of investing in China.

Chinese Biopharma Tycoons Down But Not Out In Latest Global Billionaire Ranking

China continues to dominate the latest list of global billionaires and top execs from domestic pharma firms Hengrui and Hansoh ranked among the wealthiest overall in the country, along with the founder of vaccine maker Zhifei Bio. A number of top Chinese biopharma business executives also featured in the global top 100 billionaires list.

COVID Lessons Mean New Vaccine Approach Needed In China, Exec Says

CEO of Chinese vaccine developer BravoVax shares views with Scrip on pandemic lessons learned and new approaches needed to move forward.

Table

View full table

Topics

Related Companies

Tags:
Policy China Government Payers
Latest Headlines

Keeping Track: Pharming’s Joenja, Cidara’s Rezzayo And Incyte’s Zynyz Headline US FDA Approval Bonanza

House QALY Bill Overreach Threatens Medicare Price Negotiation Program, Democrats Warn

Recent And Upcoming FDA Advisory Committee Meetings

iPLEDGE REMS: FDA Panel To Consider Changing Pregnancy Testing, Counseling Requirements

See All
UsernamePublicRestriction

Register

PS147840

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By